Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 5/20 | 0.47 |
| ▸ | THRA | P10827 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16355726 | 0.82 | ALDH1A1 (0.47) | ALDH1A1ALOX5ATM | |
| SCHEMBL30839692 | 0.76 | FSCN1 (0.43) | THRBALDH1A1 | |
| SCHEMBL14793738 | 0.75 | THRB (0.50) | THRBTHRAKDM4EALDH1A1ATM | |
| SCHEMBL15888157 | 0.73 | MEN1 (0.47) | THRBTHRAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL20748345 | 0.72 | FDPS (0.40) | THRBTHRAALDH1A1TDP1L3MBTL1 | |
| SCHEMBL30839701 | 0.72 | ALDH1A1 (0.45) | ALDH1A1PDK2TDP1 | |
| SCHEMBL8876412 | 0.71 | THRB (0.60) | THRBTHRAKDM4EALDH1A1TDP1 | |
| SCHEMBL23093089 | 0.71 | SKP2 (0.42) | KDM4EALDH1A1PPARGPPARATDP1 | |
| SCHEMBL22311333 | 0.70 | THRB (0.63) | THRBTHRAKDM4EALDH1A1ATM | |
| SCHEMBL7341507 | 0.70 | ALDH1A1 (0.40) | KDM4EALDH1A1PDK2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757093-B1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
| EP-2757093-A1 | GUANIDINOBENZOIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013039187-A1 | GUANIDINOBENZOIC ACID COMPOUND | アステラス製薬株式会社 (JP) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | SERPINB1, REN, SPINT2 | THRB 682/4885THRA 1109/4885KDM4E 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.